Anti-CD3 antibody MacroGenics Inc

Current Opinion in Investigational Drugs

Volumn 7, Issue 4, 2006, Pages 381-388

  Brown, William M ^a  

^a Paddock Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFM 15; ALPHA GALACTOSYLCERAMIDE; ANTIHISTAMINIC AGENT; AUTOANTIGEN; CYCLOSPORIN A; GLUTAMATE DECARBOXYLASE; HUMAN OKT 3 GAMMA1[ALANINE ALANINE]; IBUPROFEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NI 0401; OKT 3; PARACETAMOL; QT 3; STREPTOZOCIN; TRX 4; UNCLASSIFIED DRUG; VISILIZUMAB;

ANEMIA; ANTIBODY STRUCTURE; ARTHRALGIA; AUTOIMMUNE DISEASE; BODY WEIGHT DISORDER; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; ECZEMA; FATIGUE; HUMAN; IMMUNE DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; LICENSING; MOUTH ULCER; MYALGIA; NAUSEA; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PSORIATIC ARTHRITIS; REVIEW; RIGOR; THROMBOCYTOPENIA; TOXICITY TESTING; UNITED STATES; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MUROMONAB-CD3;

EID: 33645794256     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. 33 Humanized, nonmitogenic OKT3 antibody, huOKT3 γ(Ala-Ala): Initial clinical experience. Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR TRANSPLANT PROC 1998 30 1369-1370
2. 51 American Diabetes Association's - 61st Scientific Sessions (Part IV) - OVERNIGHT REPORT, Philadelphia, PA, USA, 22-26 June 2001. Patterson C IDDB MEETING REPORT 2001 June 22-26
3. 47 Treatment with anti-CDS monoclonal antibody (mAb) hOKT3γ1(ala-ala) Improves glycemic control during the first year of type 1 diabetes mellitus (T1DM). Herold KC, Hagopian WJ, AugerPoumain-Ruiz E, Tailor L, Febres G, Harlan D, Bluestone JA DIABETES 2001 50 Suppl 6 Abs 138-OR
4. 72 American College of Rheumatology - 65th Annual Meeting (Part III), San Francisco, CA, USA, 11-15 November 2001. Rothschild B IDDB MEETING REPORT 2001 November 11-15
5. 43 Novel immune-based therapies for psoriasis. Kirby B, Griffiths CEM BR J DERMATOL 2002 146 4 546-551
6. 20 Insulin-dependent diabetes mellitus as an autoimmune disease. Bach JF ENDOCR REV 1994 15 4 516-542
7. 19 Peptides derived from murine insulin are diabetogenic in both rate and mice, but the disease-inducing epitopes are different: Evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Heath VL, Hutchings P, Fowell DJ, Cooke A, Mason DW DIABETES 1999 48 11 2157-2165
8. 25 New Trends in Immunosuppression - Sixth International Congress, New Drug Candidates, Salzburg, Austria, 5-8 February 2004. von Herrath M IDDB MEETING REPORT 2004 February 5-8
9. 14 American Diabetes Association - 64th Scientific Sessions (Part IV) - Overnight Report, Orlando, FL, USA, 4-8 June 2004. Mazucco R IDDB MEETING REPORT 2004 June 4-8
10. 48 Serono and Novimmune to collaborate in development of two novel treatments for autoimmune diseases. Serono SA PRESS RELEASE 2005 May 17
11. 82 Anti-CDs monoclonal antibody in development type 1 diabetes mellitus. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA N ENGL J MED 2002 346 22 1692-1698
12. 91 Insulin needs after CD3-Antibody therapy in new-onset type 1 diabetes. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L et al N Engl J Med 2005 352 25 2598-2608
13. 55 MacroGenics licenses tolerance's antibody for diabetes and autoimmune disease. MacroGenics Inc PRESS RELEASE 2005 July 18
14. 12 A single course of Anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement In C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Herold K, Gitelman S, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan D, Bluestone J DIABETES 2005 54 6 1763-1769
15. 24 PDL announces strong second quarter 2005 financial results. Protein Design Labs Inc PRESS RELEASE 2005 August 04
16. 76 DlaPep277 (DeveloGen). Giannoukakis N CURR OPIN INVEST DRUGS 2005 6 10 1043-1050
17. 82 Homeostatic control of immunity by TCR peptide-specific Tregs. Lan RY, Ansari AA, Lian ZX, Gershwin ME Autoimmunity Rev 2005 4 6 351-363
18. 57 Biocon - Symbiosis partnering for life. Biocon Ltd ANNUAL REPORT 2005 March 31
19. 63 Profile and Pipeline. Affimed Therapeutics AG COMPANY WORLD WIDE WEB SITE 2005 December 05
20. 33 Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Mallone R, Nepom GT AM J THER 2005 12 6 534-550
21. 34 Therapeutic targets for the prevention of type 1 diabetes mellitus. Singh N, Palmer JP CURR DRUG TARGETS-IMMUNE ENDOCR METAB DISORD 2005 5 2 227-236
22. 35 Treatment of type 1 diabetes with anti-T-cell agents: From T-cell depletion to T-cell regulation. Glandt M, Herold KC CURR DIABETES REP 2004 4 4 291-297
23. 36 In vitro characterization of five humanized OKT3 effector function variant antibodies. Xu D, Alegre ML, Varga SS, Rothermal AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK et al CELL IMMUNOL 2000 200 1 16-26
24. 38 Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Chatenoud L, Thervet E, Primo J, Bach J-F PROC NATL ACAD SCI USA 1994 93 1 123-127
25. 52 Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA DIABETES RES 1985 2 6 271-278
26. 54 Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function. Miami Cyclosporine Diabetes Study Group. Skyler JS, Rabinovitch A J DIABETES COMPLICAT 1992 6 2 77-88
27. 56 Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S N ENGL J MED 1988 319 10 599-604
28. 80 Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA J CLIN INVEST 2003 111 3 409-418
29. 82 Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR J RHEUMATOL 2002 29 9 1907-1913
30. + Tregs. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC J CLIN INVEST 2005 115 10 2904-2913
31. 00 Humanized OKT3 antibodies: Successful transfer of immune modulating properties and idiotype expression. Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA J IMMUNOL 1992 148 9 2756-2763
32. 01 OKT3 F(ab′)2 fragments - retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA TRANSPLANTATION 1991 52 2 354-360
33. 05 Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA TRANSPLANTATION 1991 52 2 361-368
34. 07 T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA TRANSPLANT PROC 1991 23 1 Pt 1 81-82
35. 18 T lymphocyte activation following OKT3 treatment. Ellenhorn JD, Woodle ES, Thistlethwaite JR, Bluestone JA CURR SURG 1990 47 6 458-459
36. 19 Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Ellenhorn JD, Woodle ES, Ghobrial I, Thistlethwaite JR, Bluestone JA TRANSPLANTATION 1990 50 4 608-612
37. 35 Naïve T cells are resistant to anergy induction by anti-CD3 antibodies. Andris F, Denanglaire S, de Mattia F, Urbain J, Leo O J IMMUNOL 2004 173 5 3201-3206
38. 47 Effects of cyclosporine A on immune activation markers in patients with active proriasis. Economidou J, Barkis J, Demetriou Z, Avgerinou G, Psarra K, Degiannis D, Vareltzidis A, Katsambas A DERMATOLOGY 1999 199 2 144-148
39. 52 IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporine. Christie MR, Molvig J, Hawkes CJ, Carstensen B, Mandrup-Poulsen T, Canadian-European Randomised Control Trial Group DIABETES CARE 2002 25 7 1192-1197
40. 19 Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Faulds D, Goa XL, Benfield P DRUGS 1993 45 6 953-1040
41. 21 The effects of azathioprine, cyclosporine A and insulin on the in vitro lymphocyte-mediated cytotoxicity in type 1 diabetic patients. Horvath M, Varsanyi M, Bandi E, Balazsi I, Romics L EXP CLIN ENDOCRINOL 1992 100 3 90-94
42. 22 Induction of tolerance to autoimmune diabetes with islet antigens. Herodi KC, Montag AG, Buckingham F J EXP MED 1992 176 4 1107-1114
43. 91 Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. von Herrath MG, Coon B, Wolfe T, Chatenoud L J IMMUNOL 2002 168 2 933-941
44. 92 Peptide-MHC class II dimmers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA J IMMUNOL 2003 171 10 5587-5595
45. 93 Modulation of CD3 T cell function by soluble MHC II-peptide chimeras. Casares S, Bona CD, Brumeanu TD INT REV IMMUNOL 2001 20 5 547-573
46. 03 Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-de-Moraes M et al NAT MED 2001 7 9 1057-1062
47. 14 Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 85 peptide GAD(500-585). Han G, Li Y, Wang J, Wang R, Chen G, Song L, Xu R, Yu M, Wu X, Qian J, Shen B J IMMUNOL 2005 174 8 4516-4524
48. 16 DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation wthh a specific Th2/3 CD4 T cell response in non-obese diabetic mice. Gauvrit A, Debailleul M, Vu AT, Sai P, Bach JM CLIN EXP IMMUNOL 2004 137 2 253-262
49. 17 Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, Woods C, von Herrath M J IMMUNOL 2001 167 5 2950-2955
50. 18 Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic β cells. Hugues S, Mougneau E, Ferlin W, Jeske D, Hofman P, Homann D, Beaudoin L, Schrike C, von Herrath M, Lehuen A, Glaichenhaus N IMMUNITY 2002 16 2 169-181
51. 30 Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Mottram PL, Murray-Segal LJ, Han W, Maguire J, Stein-Oakley AN TRANSPLANT IMMUNOL 2002 10 1 63-72
52. 31 Clinical experience with tha use of cyclosporine A in psoriasis. Results of a retrospective study. Ojeda R, Sanchez Regana M, Massana J, Oliete R, Umbert P J DERMATOL TREAT 2005 16 4 238-241
53. 33 Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ ARCH DERMATOL 2005 141 12 1537-1541
54. 35 Pathogenesis of psoriatic arthritis. Ritchlin CT CURR OPIN RHEUMATOL 2005 17 4 406-412
55. 36 Psoriatic arthritis and psoriasis: Need for a multidisciplinary approach. Qureshi AA, Husni ME, Mody E SEMIN CUTAN MED SURG 2005 24 1 46-51
56. 37 Factors that regulate naturally occurring T regulatory cell-mediated suppression. Goleva E, Cardona ID, Ou LS, Leung DY J ALLERGY CLIN IMMUNOL 2005 116 5 1094-1100
57. 38 Role of regulatory T cells in human diseases. Chatila TA J ALLERGY CLIN IMMUNOL 2005 116 5 949-959
58. 40 CD3-specific antibodies restore self-tolerance: Mechanism and clinical applications. Chatenoud L CURR OPIN IMMUNOL 2005 17 6 632-637
59. 43 Thymic regulatory T cells. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F AUTOIMMUNITY REV 2005 4 579-586
60. 49 The role of T cells in cutaneous autoimmune disease. Chow S, Rizzo C, Ravitskiy L, Sinha AA AUTOIMMUNITY 2005 38 4 303-317
61. 54 Getting under the skin: The immunogenetics of psoriasis. Bowcock AM, Krueger JG NAT REV IMMUNOL 2005 5 9 699-711
62. 57 The genetics of psoriasis and autoimmunity. Bowcock AM ANNU REV GENOMICS HUM GENET 2005 6 93-122
63. 76 Psoriasis pathophysiology: Current concepts of pathogenesis. Krueger JG, Bowcock A ANN RHEUM DIS 2005 64 Suppl 2 30-36
64. 77 Immune deviation strategies in the therapy of psoriasis. Ghoreschi K, Rocken M CURR DRUG TARGETS-INFLAMM ALLERGY 2004 3 2 193-198
65. 78 Novel biologic therapies for psoriasis. Barry J, Kirby B EXPERT OPIN BIOL THER 2004 4 6 975-987
66. + regulatory T cell selection. Caton AJ, Cozzo C, Larkin J 3rd, Lerman MA, Boesteanu A, Jordan MS ANN NY ACAD SCI 2004 1029 101-114
67. 86 HLA-CW*602 is a susceptibility factor in type 1 psoriasis, and evidence Ala-73 is increased in male type 1 psoriatics. Mallon E, Bunce M, Wojnarowska F, Wlesh K J INVEST DERMATOL 1997 109 183-186
68. 88 Psoriasis and bacterial superantigens - formal or causal correlation? Boehncke WH TRENDS MICROBIOL 1996 4 12 485-489
69. 91 Regulatory T cells in psoriasis. Kagen MH, McCormick TS, Cooper KD ERNST SCHERING RES FOUND WORKSHOP 2006 56 193-209
70. 93 Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Parving HH, Tamow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J DIABETES CARE 1999 22 3 478-483
71. 96 Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Bisikirska BC, Herold KC ANN NY ACD SCI 2004 1037 1-9
72. 33 Anti-CD3 antibodies OKT3 and hOKT3γ1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Popma SH, Griswold DE, Li L INT IMMUNOPHARMACOL 2005 5 1 155-162.
73. 34 Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T et al AM J TRANSPLANT 2004 4 3 390-401.
74. 47 Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, hOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR Jr TRANSPLANTATION 1999 68 5 608-616
75. 08 T helper cell subsets in insulin-dependent diabetes. Katz JD, Benoist C, Mathis D SCIENCE 1995 268 5214 1185-1188.
76. + antigen-specific regulatory T cells. Bluestone JA, Tang Q PROC NATL ACAD SCI USA 2004 101 Suppl 2 14622-14626
77. 51 MacroGenics. MacroGenics Inc COMPANY WORLD WIDE WEB SITE 2006 March 15
78. 80 Complications and monitoring of OKT3 therapy. Thistlethwaite JR Jr, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP AM J KIDNEY DIS 1988 11 2 112-119
79. 02 Anti-TNF-α agents in the treatment of psoriatic arthritis. Brandt J, Braun J EXPERT OPIN BIOL THER 2006 6 2 99-107.
80. 60 Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept. Romero Crespo I, Anton Torres R, Borras Blasco J, Navarro Ruiz A FARM HOSP 2005 29 3 171-176
81. 41 Clinicaltrials.gov: hOKT3γ1 (Ala-Ala) for the treatment of psoriatic arthritis. WEB SITE 2006 http://www.clinicaltrials.gov